.jpg "Aerie Pharma (NASDAQ: AERI)")
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (NASDAQ: AERI), SCYNEXIS (NASDAQ: SCYX) and Intercept Pharma (NASDAQ: ICPT).
Aerie Pharma (NASDAQ: AERI)
Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Aerie Pharma (NASDAQ: AERI) today and set a price target of $86. The company’s shares opened today at $50.40.
Steadman commented:
“We continue to view Aerie positively, with catalysts for Roclatan, OUS geographies and additional clinical progression as potential inflection points that build on what will likely be solid acceptance of Rhopressa. We maintain our BUY rating and DCF-driven $86 PT on AERI shares.”
According to TipRanks.com, Steadman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.0% and a 36.3% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $81.75, representing a 62.2% upside.
In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.
See today’s analyst top recommended stocks >>
SCYNEXIS (NASDAQ: SCYX)
In a report released today, Alan Carr from Needham maintained a Hold rating on SCYNEXIS (NASDAQ: SCYX). The company’s shares opened today at $1.33.
Carr commented:
“Scynexis reported quarterly financial results last wk and we met w/ mgmt today for an update. Key upcoming events include top-line results from the Phase 2b trial of oral Candidiasis (VVC). Scynexis previously established clinical activity of SCY-078 in this patient population in 2016 at high doses, but w/ mild GI adverse events. We await insight into safety and tolerability of alternative lower-dose regimens and maintain HOLD. Nevertheless, we believe the commercial opportunity in VVC may be attractive and is likely underappreciated by investors. There is only one oral drug available for VVC (fluconazole). VVC is common and many patients (at least 5%, conservatively) respond inadequately. A new oral antifungal w/ a different mechanism of action could be an attractive second option for patients.”
According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.4% and a 42.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
SCYNEXIS has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
Intercept Pharma (NASDAQ: ICPT)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $203. The company’s shares opened today at $71.23.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.8% and a 44.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $121, representing a 69.9% upside.
In a report issued on May 9, Cowen & Co. also maintained a Buy rating on the stock with a $88 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
